Medmira Inc (TSE:MIR)
:MIR
Top Page
Medmira
(MIR)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.07
▼(-4.29% Downside)
Action:ReiteratedDate:03/13/26
The score is primarily weighed down by weak financial performance (ongoing losses, cash burn, negative equity, and high leverage). Technical indicators add mild downside bias (negative MACD and price below the 200-day average), while valuation is constrained by loss-making status and no dividend support.
Positive Factors
Proprietary platform
MedMira’s proprietary Rapid Vertical Flow Technology is a durable competitive asset: it enables multiple rapid-test formats, supports internal product development and third-party licensing, and creates technical differentiation that can sustain market access and partnership opportunities over months as new assays leverage the same platform.
Negative Factors
Negative equity and high leverage
Negative equity and heavy debt relative to assets materially weaken the balance sheet, reducing financial flexibility and increasing insolvency risk. This elevated leverage makes the company reliant on external financing or restructuring, limiting ability to invest in commercialization or weather shocks in the 2–6 month horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary platform
MedMira’s proprietary Rapid Vertical Flow Technology is a durable competitive asset: it enables multiple rapid-test formats, supports internal product development and third-party licensing, and creates technical differentiation that can sustain market access and partnership opportunities over months as new assays leverage the same platform.
Read all positive factors
Medmira (MIR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$44.21M
Dividend YieldN/A
Average Volume (3M)94.91K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue Growth-41.70%
EPS Growth-35.42%
CountryCA
Employees65
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding701,730,600
10 Day Avg. Volume79,718
30 Day Avg. Volume94,909
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)-2.47
Price to Sales (P/S)232.06
P/FCF Ratio-17.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medmira Business Overview & Revenue Model
Company Description
Medmira Inc. (MIR) is a Canadian biotechnology company primarily focused on the development and commercialization of rapid diagnostic tests for various infectious diseases. The company operates in the healthcare sector, specializing in point-of-ca...
How the Company Makes Money
Medmira generates revenue through the sale of its rapid diagnostic tests to healthcare providers, laboratories, and distributors across multiple regions. The company has established key revenue streams that include direct sales of its products, li...
Medmira Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
18
Very Negative
| Breakdown | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 240.51K | 412.57K | 432.53K | 952.13K | 2.14M |
| Gross Profit | -990.25K | 226.49K | -434.91K | 304.03K | 1.72M |
| EBITDA | -3.13M | -2.13M | -1.58M | -1.07M | 185.30K |
| Net Income | -4.52M | -3.33M | -2.68M | -1.83M | -675.80K |
Balance Sheet | |||||
| Total Assets | 3.68M | 6.07M | 3.65M | 3.83M | 3.89M |
| Cash, Cash Equivalents and Short-Term Investments | 14.91K | 2.10M | 13.18K | 33.46K | -2.30M |
| Total Debt | 10.71M | 9.56M | 9.27M | 8.30M | 11.54M |
| Total Liabilities | 26.24M | 24.11M | 18.68M | 16.19M | 19.61M |
| Stockholders Equity | -22.56M | -18.04M | -15.03M | -12.36M | -15.72M |
Cash Flow | |||||
| Free Cash Flow | -3.15M | -3.68M | -1.27M | -1.95M | -541.19K |
| Operating Cash Flow | -3.15M | -2.94M | -1.27M | -1.88M | -504.64K |
| Investing Cash Flow | -7.47K | -742.53K | -1.27K | -69.72K | -36.55K |
| Financing Cash Flow | 1.07M | 5.77M | 1.25M | 1.99M | 139.32K |
Medmira Technical Analysis
Negative
0.07
Price Trends
0.06
Negative
0.07
Negative
0.07
Negative
Market Momentum
>-0.01
Positive
46.83
Neutral
38.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.83 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MIR.
Medmira Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | C$50.54M | 95.68 | 3.31% | ― | 5.29% | -29.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$52.16M | -5.76 | ― | ― | ― | 54.38% | |
45 Neutral | C$31.17M | -6.85 | -8.01% | ― | -26.81% | -161.24% | |
45 Neutral | C$29.83M | -6.55 | ― | ― | ― | 72.92% | |
42 Neutral | C$44.21M | -17.16 | ― | ― | -41.70% | -35.42% |
* Healthcare Sector Average
TSE:MIR
Medmira
0.06
-0.02
-25.88%
TSE:COV
Covalon Technologies
1.83
-0.47
-20.43%
TSE:MBX
Microbix Biosystms
0.23
-0.18
-45.12%
TSE:SVA
Sernova
0.15
-0.04
-18.92%
TSE:NRX
NurExone Biologic
0.65
-0.02
-2.99%
TSE:DTC
Defence Therapeutics
0.52
-0.45
-46.39%
Medmira Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related AnnouncementsRegulatory Filings and Compliance
MedMira Narrows Loss as New Syphilis Test Wins Approval and MiROQ Platform Advances
Positive
Dec 31, 2025
MedMira reported first-quarter fiscal 2026 results marked by Health Canada approval of its Reveal TP rapid syphilis antibody test, enabling nationwide deployment through provincial validations and complementing its existing HIV and dual HIV/TP pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.